Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Bitcoin

product80% conf.·synced Nov 5, 2026

Cryptocurrency, down 12% in 2025, correlated to equities not commodities

52
sourced metrics
478
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Daily Issuance
225BTC
Jan 1, 2028source
Monthly Return
-19percent
Nov 30, 2026⚠ sources conflictsource
Etf Outflows
3.5billion_USD
Nov 1, 2026⚠ sources conflictsource
Drawdown From Ath
50percent
Aug 1, 2026source
Analyst Price Target
150000USD
Jul 4, 2026source
Earn Apr Offered
30percent
Jun 30, 2026source
Circulating Supply
20000000coins
May 23, 2026source
Market Share
50percent
May 23, 2026source
Margin
-38percent
May 18, 2026source
Price
75000USD
Apr 19, 2026source
Weekly Return
6percent
Apr 19, 2026source
Token Price
118561USD
Apr 18, 2026source
Percent Change Since Iran War
-16.54percent
Apr 13, 2026source
Collateral Value Ratio
98percent
Apr 13, 2026source
Percent Change 1y
-11.82percent
Apr 13, 2026source
Exchange Reserves
2.3million_btc
Apr 13, 2026source
Long Term Holder Supply Percentage
78percent
Apr 12, 2026source
Macro Target
85000USD
Apr 10, 2026source

Stated objectives

Become a larger asset class than gold

source
target: exceed 29 trillion USD market cap by 2035-01-01 00:00:00stated

Bitcoin may end the year below $100,000

source
target: 100000 USD by 2026-12-31 00:00:00stated

Bitcoin price target of $250,000 within 10 years

source
target: 250000 USD by 2035-01-01 00:00:00stated

Bitcoin price target of $50,000 in short term according to Standard Chartered forecast

source
target: 50000 stated

Bitcoin year-end price target of $100,000 according to Standard Chartered

source
target: 100000 by 2025-12-31 00:00:00stated

Bitcoin finding support at $60,000 level

source
target: 60000 stated

Defend critical support zone to avert deeper bear phase

source
target: $80,000-$82,000 stated

Bitcoin projected to reach $600,000-$700,000

source
target: 600000-700000 by 2029-09-01 00:00:00stated

Bitcoin achieving gold equivalence at $15 trillion market cap, reaching $750,000 per coin

source
target: 750000 stated

Bitcoin bull case price target if all catalysts align

source
target: 400000-500000 USD by 2026-01-01 00:00:00stated

Relationship graph · 478 connections

Covered by
114
Competes with
76
Invested in
58
Owns
42
Built on
31
regulates
28
Customer of
24
holds
12
accepts payment via
Bovada

Via News coverage

Bitdeer Converts Norway's Tydal Mine Site Into AI Data Center as Nordic GPU Race Heats Up
May 19, 2026
Eutelsat Secures €1.5B Refinancing as EP Group Launches Fnac Darty Takeover Bid
March 10, 2026
Brent crude hits seven-month high as Middle East tensions send Saudi stocks down 5%
March 7, 2026
Gold at $4,200/oz Drives EU Mining Expansions as UK Instability Fuels Safe-Haven Demand
March 5, 2026
European Natural Gas Prices Spike as UK Political Turmoil Compounds Energy Market Volatility
March 5, 2026
Rio Tinto Pursues Glencore Merger as Gold Hits $4,200 Record High
February 26, 2026
BELSHIPS, TIETOEVRY, Another 6 Companies Have A High Estimated Dividend Yield
October 16, 2024
RETAIL ESTATES, AKER, Another 4 Companies Have A High Estimated Dividend Yield
October 11, 2024
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com